Log in

goodpods headphones icon

To access all our features

Open the Goodpods app
Close icon
headphones
Oncology for the Inquisitive Mind

Oncology for the Inquisitive Mind

Michael Fernando and Josh Hurwitz

1 Creator

1 Creator

Cancer is a fascinating but rapidly evolving discipline - it's a full-time job just keeping up to date. In this podcast, Dr Michael Fernando and Dr Joshua Hurwitz explore the latest trials, research, and practice-changing updates, as well as regular interviews with renowned oncology specialists. Ideal for those starting their training journey, established specialists and anyone interested in medical science, oncological practice, or terrible jokes. Preferably all three.

Hosted on Acast. See acast.com/privacy for more information.

bookmark
Share icon

All episodes

Best episodes

Seasons

Top 10 Oncology for the Inquisitive Mind Episodes

Goodpods has curated a list of the 10 best Oncology for the Inquisitive Mind episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to Oncology for the Inquisitive Mind for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite Oncology for the Inquisitive Mind episode by adding your comments to the episode page.

Oncology for the Inquisitive Mind - 126. Ocular Melanoma and Prostate Cancer with A/Prof Anthony Joshua
play

08/24/24 • 41 min

Oncology for the Inquisitive Mind has been privileged to interview some truly brilliant specialists, and this week's guest is no exception. Professor Anthony Joshua is the Head of Oncology at the Kinghorn Cancer Centre and St Vincent's Health in Sydney. He is a globally recognised expert in genitourinary cancers and melanoma, with a special interest in ocular melanoma.


Professor Joshua completed his PhD in prostatic carcinogenesis under the supervision of Dr Jeremy Squire and a clinical fellowship under Dr Ian Tannock. He worked at Princess Margaret Cancer Centre before returning down under and has helped reshape cancer care at the Kinghorn Cancer Centre, making it one of the largest trial centres in New South Wales. Today, Professor Joshua discusses his journey, the landscape of prostate cancer, and some of his research in the area of ocular melanoma.


Professor Anthony Joshua is not a professional British boxer. To find out more about Professor Anthony Joshua's research portfolio, click here


For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Spotify Link to Prof Joshua's podcast, Dangerous Ideas in Drug Development: https://podcasters.spotify.com/pod/show/necta


Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.


Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/


Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.



Hosted on Acast. See acast.com/privacy for more information.

bookmark
plus icon
share episode
Oncology for the Inquisitive Mind - 91. On the Road with Dr. Ann Partridge

91. On the Road with Dr. Ann Partridge

Oncology for the Inquisitive Mind

play

02/24/24 • 43 min

In this episode, Josh interviewed Dr Ann Partridge, the director of the adult survivorship program at the Dana-Farber Institute. She is the co-founder and director of the Program for Young Women with Breast Cancer and is passionate about communication, risk perception and behavioural aspects of cancer care. Dr Partridge is the principal investigator for the Young Women’s Breast Cancer study, which has currently enrolled over 1300 women throughout the United States, and has chaired both ASCO’s scientific program committee and the ESMO-sponsored Breast Cancer in Young Women Conference. In 2018, Dr Partridge was recognized with the American Association for Cancer Research's Outstanding Investigator Award for Breast Cancer Research.


The Kinghorn Cancer Centre and The Beverley Alt Scholarship proudly support this mini-series.


The Kinghorn Cancer Centre: https://tkcc.org.au/

Dana Farber Cancer Institute: https://www.dana-farber.org/


For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]


Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/


Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Minor edits have been made to the episode to improve sound quality and flow.



Hosted on Acast. See acast.com/privacy for more information.

bookmark
plus icon
share episode
Oncology for the Inquisitive Mind - 93. On the Road with Prof. Elgene Lim

93. On the Road with Prof. Elgene Lim

Oncology for the Inquisitive Mind

play

03/09/24 • 32 min

In this episode, Josh interviews the man who helped make this grand adventure possible, his mentor, Professor Elgene Lim of the Kinghorn Cancer Centre in Sydney. Professor Lim is a medical oncologist specialising in breast cancer research. He has previously worked at the Walter and Eliza Hall Institute, completing his PhD under the mentorship of Dr Geoffrey Lindeman and Dr Jane Visvader with research focussed on identifying culprit cells in BRCA1 mutant gene carriers. He subsequently worked with Dr Eric Winer and Dr Myles Brown at the Dana-Farber Cancer Institute and Harvard Medical School. As if this was not enough, Elgene is proud of his volunteer work with asylum seekers and his work with the Asha Kiran Hospital in Orissa, India, in a program of expertise transfer and partnership with local doctors.


The Kinghorn Cancer Centre and The Beverley Alt Scholarship proudly support this mini-series.


The Kinghorn Cancer Centre: https://tkcc.org.au/

Dana Farber Cancer Institute: https://www.dana-farber.org/


For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]


Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/


Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Minor edits have been made to the episode to improve sound quality and flow.



Hosted on Acast. See acast.com/privacy for more information.

bookmark
plus icon
share episode
Oncology for the Inquisitive Mind - 90. On the Road with Dr. Harold J Burstein

90. On the Road with Dr. Harold J Burstein

Oncology for the Inquisitive Mind

play

02/17/24 • 58 min

In this episode, Josh interviews Dr Harold Burstein. A graduate of Harvard University and Harvard Medical School, Dr Burstein’s initial PhD was in cellular immunology. After receiving his oncology fellowship at the Dana Farber Cancer Institute, he joined the staff in 1999. Hal has a particular interest in breast cancer and has participated in national and international clinical trials while also working to develop treatment guidelines worldwide. A passionate educator, Dr. Burstein teaches medical students, residents and fellows at Harvard Medical School and the Dana Farber Cancer Institute.


The Kinghorn Cancer Centre and The Beverley Alt Scholarship proudly support this mini-series.


The Kinghorn Cancer Centre: https://tkcc.org.au/

Dana Farber Cancer Institute: https://www.dana-farber.org/


For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]


Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/


Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Minor edits have been made to the episode to improve sound quality and flow.



Hosted on Acast. See acast.com/privacy for more information.

bookmark
plus icon
share episode
Oncology for the Inquisitive Mind - 114. ASCO 2024 - Early Colorectal Cancer

114. ASCO 2024 - Early Colorectal Cancer

Oncology for the Inquisitive Mind

play

06/12/24 • 23 min

ASCO 2024 never seems to end, and today, Michael and Josh do a bit of a backflip and report on the advancements in early colorectal cancer. Forever a confusing topic with PRODIGE23, OPRA, and many other rectal cancer trials and a spattering of neoadjuvant colorectal trials, the ability to redefine and provide clarity to this area is pertinent. Today, it heavily focuses on immunotherapy in the colon space with sintilimab and IBI310 battling it out with the old master pembrolizumab. The rectal contingent is the TNTCRT trial, looking at total neoadjuvant therapy vs concurrent chemoradiotherapy. While the world may have moved forward, this trial could provide further evidence of the path we should be taking.


Links to studies discussed in this episode (subscription may be required)

NEOPRISM-CRC: Link

TNTCRC: Link

Neoadjuvant treatment of IBI310 (anti-CTLA-4 antibody) plus sintilimab (anti-PD-1 antibody) in patients with microsatellite instability-high/mismatch repair-deficient colorectal cancer: Results from a randomized, open-labelled, phase Ib study: Link


For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]


Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.


Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/


Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.



Hosted on Acast. See acast.com/privacy for more information.

bookmark
plus icon
share episode
Oncology for the Inquisitive Mind - 82. Metastatic triple negative breast cancer (TNBC)
play

12/16/23 • 35 min

Oncology for the Inquisitive Mind would like to issue a formal mae culpa to our listeners. You have joined us for over 12 months and over 80 episodes and listened to our ramblings and bad jokes. And it has taken 80 episodes for us to realise we have neglected the crucial and exciting subject of metastatic triple-negative breast cancer (TNBC). But fear not! We will rectify this egregious oversight with immediate effect. TNBC remains the scourge of the usually more optimistic breast cancer space. However, the fight of the world's oncologists continues across all fronts, and TNBC is no different. In today's episode, Michael and Josh will discuss the twin pillars of modern anti-cancer therapies: antibody-drug conjugates (sacituzumab govitecan) and immunotherapy (pembrolizumab). As so often the case, this is a growth area of medical oncology and one that we are very excited to (finally) address.


Links to studies discussed in this episode (subscription may be required):

  • ASCENT: https://www.nejm.org/doi/full/10.1056/NEJMoa2028485
  • KEYNOTE-355: https://www.nejm.org/doi/full/10.1056/NEJMoa2202809

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]


Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/


Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.



Hosted on Acast. See acast.com/privacy for more information.

bookmark
plus icon
share episode
Oncology for the Inquisitive Mind - 83. World Conference on Lung Cancer (part 1)

83. World Conference on Lung Cancer (part 1)

Oncology for the Inquisitive Mind

play

12/23/23 • 36 min

ASCO and ESMO are done, and soon, 2023 itself will be in the rearview mirror. And yet, there are still conferences happening around the world; yes, we know the World Conference on Lung Cancer occurred before ESMO, but there is such a thing as too much of a good thing. Join Michael and Josh on their latest virtual journey abroad, this time to the equatorial island of Singapore, as they report on two of their favourite studies from WCLC 2023. For those who celebrate, have a Merry Christmas and a happy festive season.


Links to studies discussed in this episode (subscription may be required):

MARS-2: https://pubmed.ncbi.nlm.nih.gov/32873681/

FLAURA2: https://www.nejm.org/doi/full/10.1056/NEJMoa2306434


For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]


Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/


Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.



Hosted on Acast. See acast.com/privacy for more information.

bookmark
plus icon
share episode
Oncology for the Inquisitive Mind - 102. Hepatocellular Carcinoma

102. Hepatocellular Carcinoma

Oncology for the Inquisitive Mind

play

05/18/24 • 33 min

Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer in the world and the third or fourth leading cause of death (depending on where you do your research). Over 70% of cases are in Asian countries, predominantly due to high rates of endemic hepatitis infections.


This week, we climb a mountain in search of treatment options and advancements in this orphan cancer. Two trials are discussed: The first is HIMALAYA comparing durvalumab and tremelimumab versus the old incumbent sorafenib (tyrosine kinase inhibitor). Will immunotherapy take the reigns as the preferred agents? Our second study is Compassion-08, (Michael has an abundance of this). The trial is unique as it involves a first-in-class bispecific antibody targeting PD-1 and CTLA-4 (cadonilimab in combination with lenvatinib).


Interesting times ahead in the HCC space


Links to articles discussed in this episode (subscription may be required):

HIMALAYA: Link

COMPASSION-08: Link


For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]


Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.


Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/


Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.



Hosted on Acast. See acast.com/privacy for more information.

bookmark
plus icon
share episode
Oncology for the Inquisitive Mind - 103. Metastatic Colorectal Cancer

103. Metastatic Colorectal Cancer

Oncology for the Inquisitive Mind

play

05/25/24 • 30 min

Oncology research never sits still, nor does the desire for better treatment options for metastatic colorectal cancer. Fifty percent of diagnosed cases develop metastatic spread during their disease course. This week, we look for the "SUNLIGHT" and investigate the combination of Lonsurf with Bevacizumab and using Fruquintinib with refractory metastatic colorectal cancer.


Links to articles discussed in this episode (subscription may be required):

FRESCO-2: Link

SUNLIGHT: Link


For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]


Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.


Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/


Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.



Hosted on Acast. See acast.com/privacy for more information.

bookmark
plus icon
share episode
Oncology for the Inquisitive Mind - 113. ASCO 2024 - Metastatic Colorectal Cancer

113. ASCO 2024 - Metastatic Colorectal Cancer

Oncology for the Inquisitive Mind

play

06/11/24 • 22 min

Our 2024 ASCO epic trundles onto its next generation, advanced colorectal cancer. Over the last 10 years, treatment in this area has made incremental progress through the discovery of the clinically meaningful KRAS and BRAF mutation pathways and most recently with the potential for immunotherapy in the deficient mismatch repair (dMMR) and high microsatellite instability (MSI-H) subgroups. In this episode, Josh and Michael examine studies looking at KRAS G12C-mutated, HER2-positive and dMMR colorectal cancer, as well as a very exciting study examining the utility of transplantation in patients with liver-only colorectal metastases.


Links to studies discussed in this episode (subscription may be required):

CODEBREAK300: https://meetings.asco.org/2024-asco-annual-meeting/15829?presentation=234200%23234200

MOUNTAINEER: https://meetings.asco.org/2024-asco-annual-meeting/15829?presentation=231646%23231646

CHECKMATE 8HW: https://meetings.asco.org/2024-asco-annual-meeting/15828?presentation=231645%23231645

TRANSMET: https://meetings.asco.org/2024-asco-annual-meeting/15828?presentation=231641%23231641


For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]


Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.


Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/


Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.



Hosted on Acast. See acast.com/privacy for more information.

bookmark
plus icon
share episode

Show more best episodes

Toggle view more icon

FAQ

How many episodes does Oncology for the Inquisitive Mind have?

Oncology for the Inquisitive Mind currently has 150 episodes available.

What topics does Oncology for the Inquisitive Mind cover?

The podcast is about Life Sciences, Health & Fitness, Cancer, Research, Medicine, Podcasts, Science, Oncology and Medical Education.

What is the most popular episode on Oncology for the Inquisitive Mind?

The episode title '81. San Antonio Breast Cancer Symposium Update' is the most popular.

What is the average episode length on Oncology for the Inquisitive Mind?

The average episode length on Oncology for the Inquisitive Mind is 34 minutes.

How often are episodes of Oncology for the Inquisitive Mind released?

Episodes of Oncology for the Inquisitive Mind are typically released every 4 days.

When was the first episode of Oncology for the Inquisitive Mind?

The first episode of Oncology for the Inquisitive Mind was released on Jul 31, 2022.

Show more FAQ

Toggle view more icon

Comments